MarketCap
Facebook
X
Telegram
Navidea Biopharmaceuticals ROE Ratio | NAVB
Annual ROE Ratio Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 179.91 | 11009.17 | -814.96 | 679.05 | -924.97 | 658.6 | 21.0 | 50.76 | 119.87 | 342.98 | 2074.69 | 26.56 | -1209.29 | 401.28 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11009.17 | -1209.29 | 901.05 |
Quarterly ROE Ratio Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -359.96 | -362.71 | 320.62 | 305.62 | 233.98 | 72.02 | -63.51 | -187.88 | -1894.6 | -1724.17 | -1530.58 | -1461.22 | -1057.29 | 531.32 | 855.95 | 709.24 | 424.38 | -92.57 | -131.86 | -555.28 | -590.94 | -315.14 | -233.23 | 318.62 | 359.97 | 369.12 | 410.61 | 22.57 | 21.49 | 36.83 | 47.95 | 61.89 | 80.3 | 157.19 | 227.84 | 287.87 | 607.81 | 387.92 | 857.81 | 1047.39 | 1216.94 | 1014.15 | 393.35 | 75.89 | -367.01 | -72.66 | -34.82 | 12.7 | 69.64 | -36.02 | -20.93 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1216.94 | -1894.6 | 8.76 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
1237.56 | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-35.9 | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
19932.98 | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
23.09 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-71.33 | - | - | $ 401 M | USA |
 |
Rezolute
RZLT
|
-77.06 | $ 3.94 | 1.87 % | $ 299 M | USA |
 |
Evelo Biosciences
EVLO
|
2294.21 | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-8.68 | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
-25.73 | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
-5.91 | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
-122.61 | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
2.56 | $ 3.63 | 3.93 % | $ 795 M | Britain |
|
Amryt Pharma plc
AMYT
|
0.28 | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
-135.55 | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
9.32 | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
-40.92 | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
-87.03 | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
-24.33 | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
-55.54 | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
151.25 | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-44.71 | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-188.93 | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Фармсинтез
LIFE
|
-51.75 | - | - | - |  Russia |
 |
Cellectar Biosciences
CLRB
|
-255.25 | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
-406.45 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-70.7 | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Karuna Therapeutics
KRTX
|
-34.58 | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
-139.49 | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
20.88 | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
15.38 | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
-72.64 | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
-138.81 | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
40.23 | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-25.0 | $ 11.8 | 8.21 % | $ 932 M | USA |
|
Champions Oncology
CSBR
|
-29.83 | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
-100.64 | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
-159.25 | $ 1.72 | 2.38 % | $ 13.8 M | USA |